The clinical performance is complex and often involves multi-systematic stress. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
A platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of myeloma associated with synthetase syndrome. The platform serves the China International Medical Service System, a team of internationally authoritative experts in the field of autoimmune and rheumatic immunity, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.